TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07641140: A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

Sponsor: Lingyi Biotech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,596,240

Rescue Site Savings

+$1,721,420

Unlock Full NCT07641140 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07641140 Rescue Dossier →